AI assistant
CD PRIVATE EQUITY FUND I — Net Asset Value 2022
Nov 13, 2022
64626_rns_2022-11-13_a4a181ca-e5db-4cef-a40e-9fc23403a060.pdf
Net Asset Value
Open in viewerOpens in your device viewer
Monthly update – October 2022
CD Private Equity Fund I
==> picture [457 x 52] intentionally omitted <==
----- Start of picture text -----
NTA Gross assets Distributions per unit One month Annualised performance since
per unit (millions) (percentage of initial investment) performance [1,2] inception (August 2012) [1,2]
Last 12 months: Since inception: 258
$1.38 $55.80 37.5 cents (23%) cents (161%) 0.0% 14.6%
----- End of picture text -----
Fund update
The estimated unaudited net tangible asset value (NTA) after tax as at 31 October 2022 was $1.38[1,3] per unit (30 September 2022 was $1.52[1] per unit).
Net asset value movements for October were primarily a result of the announced 14.0 cents per unit distribution (declared: 31 October 2022, payment date: 25 November 2022). This distribution is also reflected in the aggregate distribution data above.
CD1 Fund performance
==> picture [456 x 39] intentionally omitted <==
----- Start of picture text -----
1 Month 3 Months 6 Months 1 Year 3 Years p.a. 5 Years p.a. Since inception p.a. [3]
NTA return [1,2] 0.0% 5.6% 7.0% 19.1% 18.5% 20.5% 14.6%
----- End of picture text -----
On an NTA/Internal Rate of Return (IRR) basis CD1 has achieved a return of 12.8% per annum since inception.
CD1 commitment asset allocation
==> picture [198 x 22] intentionally omitted <==
----- Start of picture text -----
LP commitments to underlying managers
(US$69.8m)
----- End of picture text -----
==> picture [439 x 172] intentionally omitted <==
----- Start of picture text -----
Distribution DFW
Software & Business Encore
Technology 9.4% Services $5.0
$10.0
4.0% US Select
24.3% FPC
Healthcare Direct
10.8% $13.0 $4.0
$10.0 Incline
10.8%
Manufacturing $10.0
Trivest
4.6%
36.2% $4.8 $10.0
Telecommunications $3.0
KarpReilly
Consumer & Retail Prometheus
Peppertree
----- End of picture text -----
cdfunds.com.au ARSN 158 625 284
T 1300 454 801 F 1300 883 159 E [email protected]